Ronald van Brempt
Chief Medical Officer, Aboleris Pharma
Ronald Van Brempt, MD, MSc, is Chief Medical Officer of Aboleris Pharma. He trained in medicine, anesthesiology and intensive care at KU Leuven, Johns Hopkins and Boston Children's Hospital/Harvard. He later spent over a decade in pediatric intensive care at Leiden University Medical Center, where he went on to lead lung regeneration research. He also holds an MSc in Structural Molecular Biology from Birkbeck, University of London, and is an inventor on two patents.
Presentation: Immune Tolerance, Restored – Towards a cure for autoimmune diseases
ABO21009: a first-in-class anti-CD45RC antibody to restore immune tolerance in autoimmune disease
ABO21009 targets CD45RC, which is highly expressed on effector T cells, B cells and plasmablasts but low or absent on regulatory T cells (Tregs) and memory cells. It depletes pathogenic CD45RChigh cells, preserves memory recall responses, and expands Tregs with a suppressive (HOPX-associated) transcriptional signature. In preclinical models it prevented collagen-induced arthritis and abolished autoantibody deposition in APECED. In healthy volunteers (n=24), single ascending doses were well tolerated and confirmed target engagement. Dosing in rheumatoid arthritis patients is ongoing.
| Contact | Connect | ||||
| Veerstraat 37 1211 HJ Hilversum Chamber of Commerce: 32110979 VAT no: NL8184.34.491.B01 |
| Register now | |||
© Copyright 2023 by Hyphen Projects | All rights reserved |